|Videos|July 23, 2021
Orca-T for Graft-Versus-Host Disease: Mehrdad Abedi, MD
Author(s)Mehrdad Abedi, MD
The professor of medicine at the UC Davis Comprehensive Cancer Center discussed Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.
Advertisement
This content originally appeared on our sister site, Targeted Oncology.
Targeted Oncology spoke with Mehrdad Abedi, MD, a professor of cancer, hematology/oncology, and internal medicine in the Department of Internal Medicine, Division of Hematology and Oncology at the UC Davis Comprehensive Cancer Center, about Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease (GVHD).
The therapy was developed by Orca Bio, who approached UC Davis a few years ago to start collaborative research with the Good Manufacturing Practice facility and produce these products. Each graft of the Orca-T product has stem cells and immune cells in it. The stem cells are needed to maintain the graft and allow the product to stay in the patient for a long time, according to Abedi. The immune cells cause graft-vs-leukemia effects, which is what they want.
Abedi says it is clear that there is a population of T cells called T-regulatory cells that can prevent GVHD as seen in work from multiple investigators. There are other populations, such as the naïve T cells or conventional T cells, that can cause GVHD. A smaller number of those cell may be helpful; they can cause graft-vs-leukemia, but not GVHD.
The graft is designed so that the investigators can give stem cells, but they remove a lot of conventional T cells that can cause GVHD. The graft provides a small amount of conventional T cells that can cause graft-vs-leukemia effects, as well as the regulatory T cells that can prevent GVHD, Abedi explains.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
- Annaiz Grimm, BS, on Using EngTregs to Treat Autoimmune Disease
August 28th 2025